Maude Dubé-Pelletier - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Maude Dubé-Pelletier

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Current Oncology (Toronto, Ont.)|April 3, 2021

Routine Neuroimaging in Patients with Stage IV Non-Small Cell Lung Cancer: A Single Center ExperienceMaude Dubé-Pelletier, Catherine Labbé

The Oncologist|June 26, 2023

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung CancerMaude Dubé-Pelletier, Catherine Labbé, Jimmy Côté, et al.

Current Oncology (Toronto, Ont.)|March 27, 2026

PD-L1 Negative Advanced Non-Small Cell Lung Cancer: Practice Patterns and Real-World OutcomesAudrey-Ann Bégin, Maude Dubé-Pelletier, Catherine Labbé, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Current Oncology (Toronto, Ont.)|April 3, 2021

Routine Neuroimaging in Patients with Stage IV Non-Small Cell Lung Cancer: A Single Center ExperienceMaude Dubé-Pelletier, Catherine Labbé

The Oncologist|June 26, 2023

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung CancerMaude Dubé-Pelletier, Catherine Labbé, Jimmy Côté, et al.

Current Oncology (Toronto, Ont.)|March 27, 2026

PD-L1 Negative Advanced Non-Small Cell Lung Cancer: Practice Patterns and Real-World OutcomesAudrey-Ann Bégin, Maude Dubé-Pelletier, Catherine Labbé, et al.

Pageof 1